Navigation Links
The APR Hip Family - Porous HA

ProductsThe APR Hip Family - Porous HA
Company Zimmer, Inc.
Item The APR Hip Family - Porous HA
Features The first hydroxylapatite coating over CSTi. HA porous surfaces are clinically proven to enhance bony apposition.
Description The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences.
Info Zimmer, Inc.
Customer Service: (800) 613-6131
Web site: http://www.zimmer.com

Related medicine products :

1. Surgicel Absorbable Hemostat Family
2. The Natural-Hip Family - Revision/Trauma Nonporous CoCr
3. The Natural-Hip Family - Revision/Trauma CoCr Revision
4. The Natural-Hip Family - Revision/Trauma Calcar
5. The APR Hip Family - CoCr Cemented
6. The APR Hip Family - Porous (collared)
7. The APR Hip Family - Porous (collarless)
8. The APR Hip Family - Nonporous Fully Textured The Cost-Conscious Stem
9. The Natural-Hip Family - High Demand Porous (collarless)
10. The Natural-Hip Family - High Demand Porous (collared)
11. The Natural-Hip Family - High Demand Porous (short neck)
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products:
(Date:12/3/2008)... -- Cell Therapeutics, Inc. (CTI),(Nasdaq and MTA...f interest,related to Zevalin(R) (ibritumomab tiu... of the American Society of Hematology (ASH), Dece...tion, James Bianco, M.D., CEO of Cell Therapeutics...ogy Industry Organization and Gerson Lehrman,Grou...
(Date:12/3/2008)...C,s Work Advocating for Orphans and Highly Vulnera...SHINGTON, Dec. 4 Today,...,000 end-of-year-grant from the Jolie-Pitt Foundat...mergency Presidential Initiative for the World,s C...nsure children are not left off the agenda during ...
(Date:12/3/2008)...GELES, Dec. 3 ,Bugaboo Internation...ugaboo,Americas. Boiler has been the marketing di...ars. "Kari Boiler has the Bugaboo DNA and she is n...ith the vision that Bugaboo Americas,needs in the...ternational. , (Photo: http://www.newscom....
(Date:12/3/2008)...wswire/ -- The American Society of Hematology (ASH...od specialists, will recognize the Speaker of the ...tor of the National Heart, Lung, and Blood Institu... research. The Public Service awards will be annou... Meeting in San Francisco, CA. , , The Hono...
Breaking Medicine News(10 mins):Health News:Zevalin Data to be Presented at ASH 2008 2Health News:Zevalin Data to be Presented at ASH 2008 3Health News:Zevalin Data to be Presented at ASH 2008 4Health News:Zevalin Data to be Presented at ASH 2008 5Health News:Jolie-Pitt Foundation Awards Second Grant to Global Action for Children 2Health News:Kari Boiler Named President of Bugaboo Americas 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 3
...s diagnosed with Ross River virus has been steadil... since December. Another 10 cases have been report..., reports of another 50 diagnosed cases in Western...ree weeks has prompted reasons for concern among t...
...reat breast cancer reduces the radiation time from...he patients as it is less convenient. Doctors// ...g the cancer cells. The study compares the useful...ional six-week treatment. They are also in the pro...
...at the DeCode Genetics Inc (Reykjavik company) was...ne fifth of the diabetic population in US. The I...of the gene // is not known, but is thought to reg... insulin production. The disease was studied in t...
...Nunez, Professor of Pathology, University of Michi...ure that the protein Cryopyrin is responsible for ...o autoimmune disease. // The protein Cryopyrin is... the protein produces an immune response by activa...
Other Medicine News:Health News:Western Australia Witnesses Rise In Ross River Virus Infection 2Health News:Gene Linked To Type 2 Diabetes Identified 2
(Date:12/3/2008)...ew St. Jude treatment alleviates long-term anemia ...an applications , , MEMPHIS, Tenn., Dec. 3... to insert a corrective gene into mouse blood cell...ital have alleviated sickle cell disease pathology... treated mice showed essentially no difference fro...
(Date:12/3/2008)...ARLSBAD, Calif., Dec. 3 ...unced today that OncoGenex Pharmaceuticals, Inc.,...ed Phase 2 clinical trial of,OGX-011 in combinati..."),compared to docetaxel and prednisone alone ("t...static castrate resistant prostate cancer. The cu...
(Date:12/2/2008)...HICAGO, Dec. 3 Breast-s...detection of cancers not found on mammograms or by...day at the annual meeting of,the Radiological Soc...dentify the most difficult to detect breast cancer...chel F. Brem, M.D., professor of,radiology and di...
(Date:12/2/2008)...KOKIE, Ill., Dec. 2 Horizon Therap...company, today announced that two pivotal,Phase 3...t candidate, HZT-501,met all primary endpoints. ...ion product containing ibuprofen and famotidine, d... in the incidence of non-steroidal,anti-inflammat...
Breaking Medicine Technology:Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4National Institutes of Health Awards 2425 5M Contract to SRA 1086 1National Institutes of Health Awards 2425 5M Contract to SRA 1086 2Thalidomide Improves Outcomes for Older Myeloma Patients 2992 1Thalidomide Improves Outcomes for Older Myeloma Patients 2992 2American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 2990 1American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 2990 2American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 2990 3Jefferson urologists studying regenerated neo bladder to help spinal cord injury patients 695 1Jefferson urologists studying regenerated neo bladder to help spinal cord injury patients 695 2
...kusen, Germany, May 31, 2007- Results from various...ial in patients,with advanced hepatocellular carci...nib) tablets will be presented at the Annual,Meeti...SCO) in,Chicago, USA from June 1 - 5, 2007. , On t...nalysts,will be held on June 4, 2007. Starting at ...
...into US Phase II Clinical Trials for Organ Transpl...ire-FirstCall/ --,LifeCycle Pharma announces posit...on product candidate, LCP-Tacro - Heads into US,Ph..., Today LifeCycle Pharma A/S (OMX:LCP) announces p...ogram of LCP-Tacro, a,proprietary, once-daily tacr...
Other Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3